NeuroOne Medical Technologies Corporation Q3 2026 Earnings Call Summary

NeuroOne Medical Technologies reported strong Q3 2026 earnings, with revenue growth of 16% driven by demand for the OneRF Brain Ablation System. However, recognized revenue was impacted by manufacturing lead times. Gross margins expanded to 59.9% due to a favorable product mix. The ISO 13485 certification is key for entering international markets with diagnostic and ablation product lines.

The company's backlog is attributed to supplier lead times and shifts in product mix exceeding manufacturing flexibility. The StereoCED platform is designed to address commercial risks in neurosurgical workflows and reduce procedure time bottlenecks. A second manufacturing site is expected to launch in early 2027, increasing capacity and reducing lead times.

The company is working with Zimmer Biomet for international expansions and plans to submit a 510(k) for the Basivertebral Nerve Ablation system by mid-2027. A 1-for-6 stock reverse split occurred in April 2026 to maintain compliance. The company raised $1.4 million through ATM offerings in 2026 to support working capital. Management emphasized the importance of the second manufacturing site in addressing capacity issues.